Acadian Asset Management
EWTX icon

Acadian Asset Management’s Edgewise Therapeutics EWTX Stock Holding History

Acadian Asset Management’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$67K Sell
1,669
-1,068
-39% -$36.8K ﹤0.01% 1823
2026
Q1 		$86K Buy
2,737
+1,006
+58% +$29K ﹤0.01% 1782
2025
Q4 		$42K Buy
+1,731
New +$34.7K ﹤0.01% 1817
2022
Q3 		– Sell
-20,979
Closed -$167K – 1720
2022
Q2 		$167K Buy
+20,979
New +$159K ﹤0.01% 1240

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management's EWTX Position: Q2 2026 in Review

Acadian Asset Management reduced its Edgewise Therapeutics (EWTX) stake by 39% in Q2 2026, selling an estimated $36.8K and leaving 1,669 shares worth $67K. The position accounts for ﹤0.01% of the portfolio, ranked #1823.

Acadian Asset Management first reported a position in EWTX in Q2 2022 and has held it in 4 quarters since. The position peaked at $167K in Q2 2022. 225 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Acadian Asset Management held 1,669 shares of Edgewise Therapeutics worth $67K as of Q2 2026.
  • Acadian Asset Management sold 1,068 Edgewise Therapeutics shares in Q2 2026, an estimated $36.8K.
  • Edgewise Therapeutics made up ﹤0.01% of Acadian Asset Management's portfolio in Q2 2026, its #1823 holding.
  • Acadian Asset Management first reported a position in Edgewise Therapeutics in Q2 2022 and has held it in 4 quarters since.
  • Acadian Asset Management's Edgewise Therapeutics position peaked at $167K in Q2 2022.
  • 225 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.